[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333713-105":59,"doc-detail-333713-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","writers-readers-and-erasers-rna-modifications-and-drug-resistance-in-cancer","Writers, readers, and erasers - RNA modifications and drug resistance in cancer","","Drug resistance in cancer cells reduces treatment efficacy, driving recurrence and metastasis. A key driver is epigenetic reprogramming of gene expression through RNA modifications, including m6A, m1A, m5C, m7G, pseudouridine (Ψ), and A-to-I editing. These marks control RNA splicing, translation, transport, degradation, and stability, shaping processes such as proliferation, stemness, autophagy, invasion, and apoptosis. Dysregulated RNA modifications can cause drug resistance and poor outcomes across cancers. Targeting RNA modification regulators is therefore proposed as a strategy to overcome resistance. This review synthesizes recent findings on prevalent RNA modifications in cancer drug resistance, details underlying regulatory mechanisms, and highlights current limitations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/writers-readers-and-erasers-rna-modifications-and-drug-resistance-in-cancer/333713/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/writers-readers-and-erasers-rna-modifications-and-drug-resistance-in-cancer/333713.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does drug resistance reduce cancer treatment effectiveness?","Question",{"text":112,"@type":113},"Drug resistance in cancer cells diminishes therapeutic efficacy, contributing to recurrence and metastasis during and after treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which RNA modifications are emphasized as contributors to drug resistance?",{"text":117,"@type":113},"The review focuses on m6A, m1A, m5C, m7G, pseudouridine (Ψ), and A-to-I editing.",{"name":119,"@type":110,"acceptedAnswer":120},"How can RNA modifications influence cancer progression and therapy response?",{"text":121,"@type":113},"RNA modifications regulate splicing, translation, transport, degradation, and stability, affecting proliferation, stemness, autophagy, invasion, apoptosis, and other survival pathways that support drug resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},333713,1790178121,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Chen et al. Molecular Cancer (2024) 23:178 Molecular Cancer  \n[https://doi.org/10.1186/s12943-024-02089-6](https://doi.org/10.1186/s12943-024-02089-6)  \nREVIEW Open Access  \nWriters, readers, and erasers RNA  \nmodifications and drug resistance in cancer  \nDi Chen 1†, Xinyu Gu2†, Yeltai Nurzat3†, Lixia Xu4†, Xueyuan Li 1, Lixin Wu 1, Henan Jiao 1, Peng Gao 1, Xuqiang Zhu 1*, Dongming Yan 1*, Shaohua Li5* and Chen Xue4*  \nAbstract  \nDrug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing to this resistance is the epigenetic alteration of gene expression via RNA modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), pseudouridine (Ψ), and adenosine-to-inosine (A-to-I) editing. These modifications are pivotal in regulating RNA splicing, translation, transport, degradation, and stability. Governed by “writers,” “readers,” and “erasers,” RNA modifications impact numerous biological processes and cancer progression, including cell proliferation, stemness, autophagy, invasion, and apoptosis. Aberrant RNA modifications can lead to drug resistance and adverse outcomesin various cancers. Thus, targeting RNA modification regulators offers a promising strategy for overcoming drug resistance and enhancing treatment efficacy. This review consolidates recent research on the role of prevalent RNA modifications in cancer drug resistance, with a focus on m6A, m1A, m5C, m7G, Ψ, and A-to-I editing. Additionally, it examines the regulatory mechanisms of RNA modifications linked to drug resistance in cancer and underscores the existing limitations in this field.  \nKeywords Epigenetic alterations, Drug resistance, Abnormal expression, Combination therapy, RNA modification regulators  \n†Di Chen, Xinyu Gu, Yeltai Nurzat and Lixia Xu contributed equally to this work.  \n*Correspondence:  \nXuqiang Zhu [zhuxuqiang2007@163.com](zhuxuqiang2007@163.com)[ ](zhuxuqiang2007@163.com)Dongming Yan [mrdmyan@163.com](mrdmyan@163.com)[ ](mrdmyan@163.com)Shaohua Li [18039673197@163.com](18039673197@163.com)[ ](18039673197@163.com)Chen Xue[xchenzzu@163.com](xchenzzu@163.com)  \n1Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou 450052, Henan, China  \n2Department of Oncology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471000, Henan, China  \n3State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China 4Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou 450052, Henan, China  \n5Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou 450052, Henan, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted us","cbCainBBQigH10p7","https://ap.wps.com/l/cbCainBBQigH10p7","pdf",4310452,33,"English","# Abstract\n# Introduction\n## Core cancer therapies and resistance\n## Epigenetic regulation and RNA modifications\n## Scope and significance of the review","[{\"question\":\"Why does drug resistance reduce cancer treatment effectiveness?\",\"answer\":\"Drug resistance in cancer cells diminishes therapeutic efficacy, contributing to recurrence and metastasis during and after treatment.\"},{\"question\":\"Which RNA modifications are emphasized as contributors to drug resistance?\",\"answer\":\"The review focuses on m6A, m1A, m5C, m7G, pseudouridine (Ψ), and A-to-I editing.\"},{\"question\":\"How can RNA modifications influence cancer progression and therapy response?\",\"answer\":\"RNA modifications regulate splicing, translation, transport, degradation, and stability, affecting proliferation, stemness, autophagy, invasion, apoptosis, and other survival pathways that support drug resistance.\"}]","Writers, readers, and erasers - RNA modifications and drug resistance in cancer | PDF",1790003712,83]